The company is a non-deposit-taking financial firm that provides business loans and financing solutions to individuals and corporate clients while also managing a portfolio of investments.
The company operates in a highly fragmented lending market without any identifiable cost advantage or brand power, as evidenced by low and declining returns on equity and negative revenue growth. The lack of scale and high interest costs relative to income suggest a complete absence of a competitive moat.
Management has primarily focused on reducing debt and maintaining a stagnant loan book, with no significant reinvestment in growth or shareholder returns. The low return on capital employed indicates that the current deployment of funds is barely covering the cost of capital.
The company's demise was a slow-motion train wreck caused by the lethal combination of high leverage and anemic returns. By failing to appoint a CFO, the firm lost its grip on risk management, leading to a surge in bad debt write-offs that wiped out the razor-thin interest coverage. As revenue continued its long-term contraction, the negative cash conversion cycle eventually starved the business of liquidity, forcing a fire sale of assets to service debt that the stagnant loan book could no longer support.
RichFakir rates Mathew Easow Research Securities Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mathew Easow Research Securities Ltd is trading about 14% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mathew Easow Research Securities Ltd is: Not rated. Poor business (score 26), but the valuation is low-confidence, so we are not calling it a bargain.
RichFakir's educational estimate of Mathew Easow Research Securities Ltd's fair value is about ₹12 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →